Background: Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) are both chronic, progressive inflammatory arthritis that can cause significant disability and morbidity. Depression in RA has been associated with higher levels of disease activity, pain, fatigue, work disability, lower treatment compliance and increased suicidal risk and mortality [1]. PsA patients suffer from psoriasis and joint involvement; hence have greater odds of depression by 2.1 times compared with RA [2].

Objectives: To compare the prevalence rates of depression and anxiety and its associated factors between RA and PsA patients in Hospital Putrajaya.

Methods: A cross-sectional survey using the Hospital Anxiety and Depression Scale (HADS) questionnaire were distributed to 300 patients who attended rheumatology outpatient clinic from February – April 2019. The HADS was categorized into 3 groups based on their scores 0-7 (Normal); 8-10 (Borderline); and 11-21 (Abnormal). Data on patient demographics and components of disease assessment scores were recorded. Disease activity was assessed using DAS28-ESR for all patients. Additional evaluation using Bath Ankylosing Spondylitis Disease Activity Score (BASDAI) and body surface area (BSA) were done for PsA patients. P value of < 0.05 was taken as significant.

Results: In total, 205 RA and 73 PsA patients were eligible for analysis. Majority of the patients were female, Malay and married for both groups. The mean age group for RA and PsA were 56.2 ± 11.9 years and 51.0 ± 14.6 years. The mean duration of disease for RA were 8 ± 10 years; while for PsA were 6 ± 11 years. The prevalence rates of depression and anxiety for RA were 8.3% and 13.7%; and PsA were 9.6% and 17.8% respectively. Borderline scores for depression occurred in 16.1% of RA patients and 12.3% for PsA. Twenty percent of RA patients (n=41) and twenty-four percent of PsA patients (n=18) scored borderline for anxiety. The significant positive correlations with depression and anxiety in RA include high disease activity scores (r = 0.27; r = 0.31), number of tender joints (r = 0.26; r = 0.24) and pain (r = 0.29; r = 0.27). Higher number of swollen joints significantly correlated with depression (r = 0.16) but not with anxiety. RA patients with Ischaemic Heart Disease (IHD) a heart failure have higher depression scores (p < 0.05). As for PsA group, high BASDAI score (anxiety; r = 0.34, depression; r = 0.26) and psoriasis involving head and neck region (p < 0.05) were significant associated factors. Age was inversely correlated with anxiety in the PsA group.

Conclusion: There is higher prevalence of anxiety in both RA and PsA as compared to depression. Higher disease activity scores were associated with depression and anxiety in both RA and PsA with axial involvement.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.5127

FRI0078

CHARACTERISTICS OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS

S. Takahashi1, Y. Kanoke1, T. Takeuchi1, 3Keio University School of Medicine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan

Background: Despite remarkable progress in therapy, not a few patients with rheumatoid arthritis (RA) have not achieved treatment target. Various factors can be ascribed to difficult-to-treat RA, however, little is known about their characteristics.

Objectives: To clarify characteristics of patients with difficult-to-treat RA in real-world.

Methods: We reviewed all consecutive RA patients in Keio University Hospital between 2016 and 2017 and collected medical information. We defined patients in moderate disease activity and high disease activity according to disease activity score for 28 joints (DAS28) at the last visit despite more than one year treatment for RA as difficult-to-treat RA and analyzed their clinical characteristics.

Results: A total of 1693 patients with RA were enrolled in the analysis. The mean age at the last visit was 64 years old, female was 83%, and the mean disease duration was 11.9 years. Rheumatoid factor and anti-cyclic citrullinated peptide were positive for 76% and 75% of the patients, respectively. The current treatment were conventional synthetic disease modifying anti-rheumatic drugs in 73%, biologic agents or janus kinase (JAK) inhibitors in 57%, and glucocorticoids in 13%. Disease activity according to DAS28 was remission in 65%, low disease activity in 21%, and moderate/high disease activity in 14%, which was defined as difficult-to-treat RA. Characteristics of difficult-to-treat RA were the mean age of 70 years old, female of 89%, and the mean disease duration of 14 years. The current treatment consisted of conventional synthetic disease modifying anti-rheumatic drugs alone in 40.7%, biologic agents or JAK inhibitors in 55.8%, and glucocorticoids in 29.0%. The causes of difficult-to-treat RA were unresponsiveness to several biologic agents and/or JAK inhibitors in 22.9%, comorbidities in 33.8%, and personal reasons in 39.8% (costs in 35.9%, low adherence in 4.3%, concerns about possible adverse reaction of drugs in 54.3% and high patient (global assessment in 5.4%). Patient characteristics were significantly different between the causes; age at RA onset (51 vs 61 vs 51 years, p<0.001), current age (65 vs 77 vs 66 years, p<0.001), estimated glomerular
filtration rate (75 vs 61 vs 73 mL/min/1.73m², p<0.001), tender joint count (3.4 vs 1.6 vs 2.1, p=0.005), swollen joint count (3.1 vs 1.6 vs 2.9, p=0.003), evaluator global assessment (21 vs 14 vs 16, p=0.003), health assessment questionnaire-disability index (1.3 vs 1.3 vs 0.9, p=0.005), a history of serious infection (28 vs 41 vs 13%, p<0.001) and rheumatic disease comorbidity index (1.2 vs 2.2 vs 0.9, p<0.001).

Conclusion: There are still 14% of patients with RA were difficult-to-treat in real world in spite of intensive treatment. Their characteristics are distinct by the cause of difficulty to treat, suggesting the approach to difficult-to-treat RA should be personalized.

References:


DOI: 10.1136/annrheumdis-2020-eular.872

FR10080 CLINICAL CHARACTERISTICS OF PATIENTS WITH ELDERLY-ONSET RHEUMATOID ARTHRITIS (EORA)
1Medical University of Lublin, Department of Rheumatology and Connective Tissue Diseases, Lublin, Poland; 2Samodzielny Szpital Kliniczny nr 4, Department of Rheumatology and Connective Tissue Diseases, Lublin, Poland

Background: The onset of rheumatoid arthritis (RA) occurs usually between 35-50 years of age. Since the general population is ageing, beginning of RA in older age is more common. The term elderly onset of rheumatoid arthritis (EORA) describes the disease with onset at age over 60. The term younger-onset rheumatoid arthritis (YORA) refers to the disease with typical, earlier onset. Observational studies indicate, that substantial differences do occur between the two RA subtypes (EORA and YORA).

Objectives: The goal of the study was to analyze the course of disease and treatment in EORA in comparison to YORA patients.

Methods: The study was conducted in consecutive RA patients, treated in the Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Poland. The study group consisted of 113 patients (93 female, 20 men), with the mean (SD) age 59.4 (19.0), disease duration 12.9 (10.3) years. The cut off between EORA and YORA was set at 60 years of age. There were 63 (55.8%) EORA and 50 (44.2%) YORA patients. Demographic and clinical information was obtained through structured interview, review of medical records and laboratory tests. Disease activity was assessed based on joint counts and Disease Activity Score of 28 joints (DAS28).

Disclosure of Interests: Satoshi Takanashi: None declared, Yuko Kaneko

References: [2]

FR10081 WERE FRAIL RA PATIENTS AT YOUNGER AGE MORE LONELY, DEPRESSED OR ANXIOUS THAN NON-FRAIL RA PATIENTS?
A. Van Moerbeke1, F. Cleutjens1, A. Boonen1, M. Van Onna1, 1Maastricht University Medical Center, Department of Internal Medicine, Division of Rheumatology, Maastricht, Netherlands

Background: Frailty is a state that reflects reduced reserve and resistance to stressors among elderly persons. A preceding study showed that 38 out of 90 (42%) RA patients aged ≥ 55 years who visited our outpatient clinic were frail. Presence of frailty was not age-dependent. Patients were mainly classified as frail because of positive answers on single items that report on depressive feelings (73.7%), anxiety (57.9%), missing people around (65.8%) and emptiness (63.2%) [1]. It is unclear whether frailty is a cause, consequence or comorbidity of poor psycho-emotional health. Alternatively, they could also be congruent conditions. Exploring whether poor psycho-emotional health might be a longitudinal predictor of frailty, might shed light upon the relation between frailty and psycho-emotional health.

Objectives: In this mixed qualitative / quantitative study, we assessed whether older frail RA patients were already more lonely, depressed, and/or anxious than non-frail RA patients at 40 years.

Methods: All 90 RA patients who participated in our previous study on frailty in 2017 were invited for the current study. Participants were invited to rate validated multidimensional questionnaires on depression and anxiety (Geriatric Depression Scale (GDS) and Hospital Anxiety and Depression Scale (HADS)), loneliness (de Jong Gierveld loneliness scale) social support (Social Support List) for their current situation, but also retrospectively for their situation at the age of 40. Current frailty was assessed by the Groningen Frailty Indicator (GFI).

Disclosure of Interests: Bozena Targonska-Stepniak Consultant of: Berlin-Chemie Mennarini, Sandoz, Speakers bureau: KIRA, Sandoz, Krzysztof Grzechnik: None declared, Katarzyna Kolarz: None declared, Danuta Gagol: None declared, Maria Majdan Consultant of: Roche, Amgen, Speakers bureau: Roche, Amgen

DOI: 10.1136/annrheumdis-2020-eular.800